HOYA Co. (OTCMKTS:HOCPY) Sees Significant Drop in Short Interest

HOYA Co. (OTCMKTS:HOCPY - Get Free Report) was the target of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 1,100 shares, a drop of 84.7% from the February 13th total of 7,200 shares. Based on an average daily volume of 93,500 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company's shares are short sold.

HOYA Trading Up 1.6 %

OTCMKTS:HOCPY traded up $1.88 during midday trading on Wednesday, hitting $116.78. 51,245 shares of the company traded hands, compared to its average volume of 32,789. The company has a current ratio of 5.04, a quick ratio of 4.35 and a debt-to-equity ratio of 0.02. The firm's fifty day moving average is $126.38 and its 200-day moving average is $131.53. The firm has a market capitalization of $40.39 billion, a P/E ratio of 29.72, a P/E/G ratio of 2.38 and a beta of 0.83. HOYA has a 12-month low of $108.12 and a 12-month high of $148.27.

HOYA (OTCMKTS:HOCPY - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The technology company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.01 by $0.94. HOYA had a return on equity of 21.34% and a net margin of 24.17%. On average, sell-side analysts predict that HOYA will post 3.66 EPS for the current year.

About HOYA

HOYA Corporation, a med-tech company, provides high-tech and medical products worldwide. It operates through three segments: Life Care, Telecommunication, and Other. The company offers life care products, including eyeglass and contact lenses; medical endoscopes; intraocular lenses; laparoscopic surgical instruments; automatic endoscope cleaning equipment; and other medical related products, such as prosthetic ceramic fillers and metallic implants for orthopedics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads